Advertisement
Advertisement
LEXX
Lexaria Bioscience Corp. Common Stock
0.73
USDSponsored
+0.07
+10.57%
Feb 06, 15:59 UTC -5
Closed
After-Market
0.69
-0.04
-5.05%
LEXX Earnings Reports
Positive Surprise Ratio
LEXX beat 6 of 15 last estimates.
40%
Next Report
Date of Next Report
Apr 13, 2026
Estimate for Q2 26 (Revenue/ EPS)
$102.00K
/-$0.12
Implied change from Q1 26 (Revenue/ EPS)
--
/+71.43%
Implied change from Q2 25 (Revenue/ EPS)
-41.38%
/-20.00%
Lexaria Bioscience Corp. Common Stock earnings per share and revenue
On Jan 13, 2026, LEXX reported earnings of -0.07 USD per share (EPS) for Q1 26, beating the estimate of -0.13 USD, resulting in a 47.21% surprise. Revenue reached --, compared to an expected 102.00 thousand, with a -100.00% difference. The market reacted with a +5.08% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 3 analysts forecast an EPS of -0.12 USD, with revenue projected to reach 102.00 thousand USD, implying an increase of 71.43% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Lexaria Bioscience Corp. Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Lexaria Bioscience Corp. Common Stock reported EPS of -$0.07, beating estimates by 47.21%, and revenue of $0.00, -100% below expectations.
How did the market react to Lexaria Bioscience Corp. Common Stock's Q1 2026 earnings?
The stock price moved up 5.08%, changed from $0.77 before the earnings release to $0.81 the day after.
When is Lexaria Bioscience Corp. Common Stock expected to report next?
The next earning report is scheduled for Apr 13, 2026.
What are the forecasts for Lexaria Bioscience Corp. Common Stock's next earnings report?
Based on 3
analysts, Lexaria Bioscience Corp. Common Stock is expected to report EPS of -$0.12 and revenue of $102.00K for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement